Citations

Clear

448 citation(s) found for "Ja, Fields".

Rates of lobar atrophy in asymptomatic MAPT mutation carriers
Senjem, Matthew L. , Tosakulwong, Nirubol , Lesnick, Timothy G. , Brushaber, Danielle , Dheel, Christina, Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Gearhart, Debra, Graff‐Radford, Jonathan, Graff‐Radford, Neill R., Jack, Clifford R. , Kremers, Walter K. , Rademakers, Rosa , Syrjanen, Jeremy A. , Boxer, Adam L. , Rosen, Howie, Kantarci, Kejal , Senjem, Matthew, Jack, Clifford R , Senjem, Matthew L , Kantarci, Kejal , Kremers, Walter K , Chen, Qin , Boeve, Bradley F. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Jones, David T. , Knopman, David S. , Lapid, Maria I. , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | July 30, 2019 | Volume: 5 | Issue: 1 | Pages: 338-346

10.1016/j.trci.2019.05.010 | PMID 31388560 Get It

Abstract Introduction The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule‐associated protein tau ( MAPT ) mutation carriers. Methods MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor‐based morphometry with symmetric normalization algorithm. Results The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers.
The ‘ in vivo lifestyle’ of bile acid 7α-dehydroxylating bacteria: comparative genomics, metatranscriptomic, and bile acid metabolomics analysis of a defined microbial community in gnotobiotic mice
Ridlon, Jason M. , Devendran, Saravanan , Alves, João M. P. , Doden, Heidi L. , Wolf, Patricia G. , Pereira, Gabriel Vasconcelos , Ly, Lindsey K., Volland, Alyssa , Takei, Hajime , Murai, Tsuyoshi, Kurosawa, Takao, Chlipala, George E. , Hernandez, Alvaro G. , Fields, Christopher J. , Wright, Christy L., Kakiyama, Genta , Kashyap, Purna , McCracken, Vance J. , Gaskins, H. Rex , Pereira, Gabriel V , Hernandez, Alvaro G , Wright, Christy L , McCracken, Vance, Nittono, Hiroshi , Green, Stefan J. , Cann, Isaac

Mayo Clinic

Gut Microbes | June 10, 2019 | Volume: 11 | Issue: 3 | Pages: 381-404

10.1080/19490976.2019.1618173 | PMID 31177942 Get It

Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers
Chen, Qin , Tosakulwong, Nirubol , Lesnick, Timothy G. , Brushaber, Danielle , Dheel, Christina, Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Gearhart, Debra, Haley, Dana , Gunter, Jeffrey L. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Kraft, Ruth, Rademakers, Rosa , Rosen, Howie, Boxer, Adam L. , Kantarci, Kejal , Lesnick, Timothy, Kantarci, Kejal , Boeve, Bradley F. , Jones, David T. , Knopman, David S. , Lapid, Maria I. , Wszołek, Zbigniew K.

Mayo Clinic

Journal of Neuroimaging | June 7, 2019 | Volume: 29 | Issue: 5 | Pages: 624-629

10.1111/jon.12642 | PMID 31173437 Get It

ABSTRACT BACKGROUND AND PURPOSE The objective of this study was to longitudinally investigate the trajectory of change in 1 H MRS measurements in asymptomatic MAPT mutation carriers who became symptomatic during follow‐up, and to determine the time at which the neurochemical alterations accelerated during disease progression. METHODS We identified eight MAPT mutations carriers who transitioned from asymptomatic to symptomatic disease during follow‐up. All participants were longitudinally followed with an average of 7.75 years (range 4‐11 years) and underwent two or more single voxel 1 H MRS examinations from the posterior cingulate voxel, with a total of 60 examinations. The rate of longitudinal change for each metabolite was estimated using linear mixed models. A flex point model was used to estimate the flex time point of the change in slope. RESULTS The decrease in the NAA/mI ratio accelerated 2.09 years prior to symptom onset, and continued to decline. A similar trajectory was observed in the presumed glial marker mI/Cr ratio accelerating 1.86 years prior to symptom onset. CONCLUSIONS Our findings support the potential use of longitudinal 1 H MRS for monitoring the neurodegenerative progression in MAPT mutation carriers starting from the asymptomatic stage.
Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.
Liu, Minetta C. , Jamshidi, Arash , Venn, Oliver, Fields, Alexander P. , Maher, M. Cyrus , Cann, Gordon, Amini, Hamed , Gross, Samuel, Bredno, Joerg , Miller, M. Barry, Schellenberger, Jan, Fung, Eric T. , Maddala, Tara, Oxnard, Geoffrey R. , Hartman, Anne‐Renee , Aravanis, Alex, Seiden, Michael V., Gross, Samuel, Kurtzman, Kathryn N. , Klein, Eric A. , Spigel, David R. , Aravanis, Alexander M.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 3049-3049

10.1200/jco.2019.37.15_suppl.3049 Get It

3049 Background: For multi-cancer detection using cfDNA, TOO determination is critical to enable safe and efficient diagnostic follow-up. Previous array-based studies captured < 2% of genomic CpGs. Here, we report genome-wide fragment-level methylation patterns across 811 cancer cell methylomes representing 21 tumor types (97% of SEER cancer incidence), and define effects of this methylation database on TOO prediction within a machine learning framework. Methods: Genomic DNA from 655 formalin-fixed paraffin-embedded (FFPE) tumor tissues and 156 isolated cells from tumors was subjected to a prototype 30x whole-genome bisulfite sequencing (WGBS) assay, as previously reported in the Circulating Cell-free Genome Atlas (CCGA) study (NCT02889978). Two independent TOO models, one with and one without the methylation database, were fitted on training samples; each was used to predict on the test set. A WGBS classifier was used to detect cancer at 98% specificity; reported TOO results reflect percent agreement between predicted and true TOO among those detected cancers (166 cases: 81 stage I-III, 69 stage IV, 16 non-informative). Results: Genome-wide methylation data generated from this database allowed fragment-level analysis and coverage of ~30 million CpGs across the genome (~60-fold greater than array-based approaches). Incorrect TOO assignments decreased by 35% (20% to 13%) after incorporating methylation database information into TOO classification. Improvement was observed across all cancer types and was consistent in early-stage cancers (stage I-III). Respective performances in breast cancer (n = 23) were 87% vs 96%; in lung cancer (n = 32) were 85% vs 88%; in hepatobiliary (n = 10) were 70% vs 90%; and in pancreatic cancer (n = 17) were 94% vs 100%. Results using an optimized approach informed by these results in a large cohort of CCGA participants will be reported. Conclusions: Incorporating data from a large methylation database improved TOO performance in multiple cancer types. This supports feasibility of this methylation-based approach as an early cancer detection test across cancer types. Clinical trial information: NCT02889978.
Comparative Effectiveness of Behavioral Interventions on Quality of Life for Older Adults With Mild Cognitive Impairment
Chandler, Melanie , Fields, Julie A. , Ball, Colleen T. , Phatak, Vaishali , Dean, P.M. , Morris, Miranda , Chandler, Melanie J, Locke, Dona E, Crook, Julia E. , Locke, Dona E.C. , Dean, Pamela M., Smith, Glenn E.

Mayo Clinic

JAMA Network Open | May 17, 2019 | Volume: 2 | Issue: 5 | Pages: e193016

10.1001/jamanetworkopen.2019.3016 | PMID 31099860 Get It

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Coit, Daniel G. , Thompson, John A. , Albertini, Mark R. , Barker, Christopher A. , Carson, William E. , Contreras, Carlo M. , DiMaio, Dominick J. , Fleming, Martin D. , Freeman, Morganna , Galan, Anjela , Gastman, Brian , Guild, Valerie, Johnson, Douglas B. , Lange, Julie R., Nath, Sameer K., Olszanski, Anthony J. , Ott, Patrick A. , Gupta, Aparna Priyanath , Ross, Merrick I. , Salama, April K.S. , Skitzki, Joseph J. , Sosman, Jeffrey A. , Wuthrick, Evan , McMillian, Nicole R., Engh, Anita M. , Carson, William E , Olszanski, Anthony J , Daniels, Gregory A. , Fields, Ryan C. , Joseph, Richard W. , Swetter, Susan M. , Tanabe, Kenneth K.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 367-402

10.6004/jnccn.2019.0018 | PMID 30959471 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.
Self-Efficacy Mediates the Association Between Physical Function and Perceived Quality of Life in Individuals with Mild Cognitive Impairment
Langer, Kailey , O’Shea, Deirdre , Wit, Liselotte De , DeFeis, Brittany , Mejia, Andrea, Amofa, Priscilla , Chandler, Melanie , Fields, Julie A. , Phatak, Vaishali , Dean, P.M. , Locke, Dona E.C. , De Wit, Liselotte , Mejia, Andrea, Dean, Pamela M., Smith, Glenn E.

Mayo Clinic

Journal of Alzheimer’s Disease | March 19, 2019 | Volume: 68 | Issue: 4 | Pages: 1511-1519

10.3233/jad-181020 | PMID 30909227 Get It

Background: Research has shown that individuals with mild cognitive impairment (MCI) value quality of life (QoL) above and beyond cognitive function or other potential outcomes in MCI. There is evidence supporting the negative impact of poor physical function on QoL ratings. Objective: The study explored whether a modified measure of self-efficacy for managing MCI and education mediated and/or moderated the relationship between physical function and QoL in persons with MCI. Methods: Baseline data from 200 participants with MCI were obtained from a larger study assessing the effectiveness of a behavioral intervention. Physical function was assessed by the Short Physical Performance Battery. QoL was assessed with the Quality of Life in Alzheimer’s Disease scale. Memory-related self-efficacy was assessed using a modified 9-item version of the Chronic Disease Self-Efficacy Scales. Mediation and moderation analyses tested the hypotheses that self-efficacy and education alter the association between physical function and QoL in individuals with MCI. All analyses were adjusted for age, cognitive severity, and sex. Results: Self-efficacy for managing MCI was a significant mediator of the association between physical function and perceived QoL. Individuals with better physical function reported higher self-efficacy which was associated with higher QoL ratings. Conclusions: Greater self-efficacy for managing MCI mediated the negative association between physical function and quality of life in this exploratory study. Interventions aimed at enhancing memory self-efficacy in MCI may improve perceived QoL, even in the presence of poor physical function. Future research is needed to investigate this further.
What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas, Abbie S., Porter, Alyx B. , Sharma, Akanksha , Knox, Molly, Marks, Lisa , Wingerchuk, Dean M. , O’Carroll, Cumara B. , Marks, Lisa A., Marks, Lisa A , Ornelas, Abbie S.

Mayo Clinic

The Neurologist | February 28, 2019 | Volume: 24 | Issue: 2 | Pages: 71-73

10.1097/nrl.0000000000000222 | PMID 30817495 Get It

Alternating electrical fields can disrupt mitosis leading to apoptosis of rapidly dividing cancer cells. The device that utilizes this mechanism is known as tumor-treating fields (TTFields). TTFields can be applied by ceramic transducer arrays on a shaved scalp to deliver the alternating electric activity to patients with glioblastoma (GBM). It has FDA approval for use in both recurrent and newly diagnosed GBM. The objective is to critically appraise the current evidence for the use of TTFields as adjunctive treatment to newly diagnosed GBM. The objective was addressed through the development of a structured, critically appraised topic. We incorporated a clinical scenario, background information, a structured question, literature search strategy, evidence summary, clinical bottom lines, and expert discussion. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of neurooncology. A randomized controlled trial was selected for critical appraisal. Patients with newly diagnosed GBM completing standard radiation and chemotherapy with temozolomide (TMZ) were subsequently randomized to receive maintenance TMZ with TTFields, or TMZ alone. With the addition of TTFields, median progression-free survival was 6.7 months compared with 4 months without the addition of TTFields (95% confidence interval, 0.52-0.76; P<0.001) and overall survival was 20.9 months compared with 16.0 months without the addition of TTFields (95% confidence interval, 0.53-0.76; P<0.001). TTFields may increase both progression-free and overall survival in patients receiving standard chemoradiation therapy for GBM.
Excessive Daytime Sleepiness in Major Dementia Syndromes
Boeve, Angelica, Ferman, Tanis J. , Aakre, Jeremiah A. , Silber, Michael H. , Fields, Julie A. , Graff‐Radford, Neill R. , Geda, Yonas E. , Graff-Radford, Jonathon, Petersen, Ronald C. , Aakre, Jeremiah, St Louis, Erik, Silber, Michael , Mielke, Michelle, Geda, Yonas, Boeve, Brad , Geda, Yonas E , Ferman, Tanis J , Louis, Erik K. St. , Machulda, Mary M. , Mielke, Michelle M. , Jones, David T. , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

American Journal of Alzheimer's Disease & Other Dementias® | February 11, 2019 | Volume: 34 | Issue: 4 | Pages: 261-264

10.1177/1533317519828046 | PMID 30740984 Get It

There has been no comparison of excessive daytime sleepiness (EDS) in patients with Alzheimer’s disease dementia (AD), dementia with Lewy bodies (DLB), and behavioral variant frontotemporal dementia (bvFTD). We identified patients with mild dementia who met criteria for these disorders who also had the Epworth Sleepiness Scale (ESS) completed. The sample included 17 bvFTD, 111 AD, and 31 DLB. An ESS score ≥10 was considered abnormal and consistent with EDS. Analyses with age and sex as covariates revealed higher mean ESS scores for DLB compared to the other groups (DLB 13.9 [5], bvFTD 9.6 [8], AD 8.8 [5], P < .05). An ESS score ≥10 was significantly more likely to occur in DLB compared to bvFTD or AD (DLB 81% vs bvFTD 47% vs AD 45%, P < .01). In patients with mild dementia, EDS is greatest in DLB and comparably lower in bvFTD and AD.